Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 401–500 of 1,006
The reactive oxygen‐driven tumor: relevance to melanoma
Fried, L., & Arbiser, J. L. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00451.x · Cited by 96
Downing, A., Newton‐Bishop, J., & Forman, D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603216 · Cited by 100
DNA microarray analyses of melanoma gene expression: a decade in the mines
Hoek, K. S. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00412.x · Cited by 100
B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer
Wang, J., Kobayashi, T., Floc’h, N., Kinkade, C. W., Aytés, À., Dankort, D. L., Lefèbvre, C., Mitrofanova, A., Cardiff, R. D., McMahon, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0820 · Cited by 101
Azijli, K., Stelloo, E., Peters, G. J., & van den Eertwegh, A. J. M. (2014) · PubMed · Cited by 101
Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
Ma, Y., Xia, R., Ma, X., Judson‐Torres, R. L., & Zeng, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702287 · Cited by 100
The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice
Ferrara, G., & Argenziano, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675296 · Cited by 99
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
Heinzerling, L., Kühnapfel, S., Meckbach, D., Baiter, M., Kaempgen, E., Keikavoussi, P., Schuler, G., Agaimy, A., Bauer, J. M., Hartmann, A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.143 · Cited by 99
Changes in the presentation of nodular and superficial spreading melanomas over 35 years
Warycha, M. A., Christos, P. J., Mazumdar, M., Darvishian, F., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Kopf, A. W., Polsky, D., & Osman, I. (2008) · Cancer · doi:10.1002/cncr.23955 · Cited by 99
Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3168 · Cited by 99
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
El-Osta, H., Falchook, G., Tsimberidou, A., Hong, D., Naing, A., Kim, K., Wen, S., Janku, F., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025806 · Cited by 94
Zimmer, L., Livingstone, E., Hillen, U., Dömkes, S., Becker, A., & Schadendorf, D. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2011.2842 · Cited by 98
Daud, A., & Tsai, K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 94
Tap, W. D., Gong, K.-W., Daring, J., Tseng, Y., Ginther, C., Pauletti, G., Glaspy, J. A., Essner, R., Bollag, G., Hirth, P., et al. (2010) · Neoplasia · doi:10.1593/neo.10414 · Cited by 85
Romano, G., Chen, P.-L., Song, P., McQuade, J. L., Liang, R. J., Liu, M., Roh, W., Duose, D. Y., Carapeto, F. C. L., Li, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0745 · Cited by 96
Pittoni, P., Piconese, S., Tripodo, C., & Colombo, M. P. (2010) · Oncogene · doi:10.1038/onc.2010.494 · Cited by 96
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Guo, J., Qin, S., Liang, J., Lin, T., Si, L., Chen, X., Chi, Z., Cui, C., Du, N., Fan, Y., et al. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2015.12.02 · Cited by 96
Nguyen, T.-T., Ramsay, L., Ahanfeshar-Adams, M., Lajoie, M., Schadendorf, D., Alain, T., & Watson, I. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3365 · Cited by 97
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
Cosgarea, I., Ugurel, S., Sucker, A., Livingstone, E., Zimmer, L., Ziemer, M., Utikal, J. S., Mohr, P., Pfeiffer, C., Pföhler, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16542 · Cited by 95
The specificity of UVA-induced DNA damage in human melanocytes
Mouret, S., Forestier, A., & Douki, T. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05185g · Cited by 94
Yamazaki, N., Takenouchi, T., Fujimoto, M., Ihn, H., Uchi, H., Inozume, T., Kiyohara, Y., Uhara, H., Nakagawa, K., Furukawa, H., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3237-x · Cited by 94
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Mehnert, J. M., & Kluger, H. M. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0249-5 · Cited by 97
Buac, K., Xu, M., Cronin, J., Weeraratna, A. T., Hewitt, S. M., & Pavan, W. J. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00616.x · Cited by 81
Small molecules and targeted therapies in distant metastatic disease
Hersey, P., Bastholt, L., Chiarion‐Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I. C., Robert, C., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp254 · Cited by 95
von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A. F., Michielin, O. A., Cathomas, R. L., Schläppi, M., Moch, H., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr126 · Cited by 93
Hacker, E., Hayward, N. K., Dumenil, T. D., James, M. R., & Whiteman, D. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.182 · Cited by 94
Bonazzi, V., Nancarrow, D. J., Stark, M. S., Moser, R. J., Boyle, G. M., Aoude, L. G., Schmidt, C., & Hayward, N. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026121 · Cited by 93
Review: mucosal melanoma of the head and neck
Gavriel, H., McArthur, G. A., Sizeland, A. M., & Henderson, M. A. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e3283470ffd · Cited by 93
Ny, L., Hernberg, M., Nyakas, M., Koivunen, J. P., Oddershede, L., Yoon, M., Wang, X., Guyot, P., & Geisler, J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1747636 · Cited by 93
Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 93
Geller, A. C., Elwood, M., Swetter, S. M., Brooks, D. R., Aitken, J., Youl, P. H., Demierre, M., & Baade, P. D. (2009) · Cancer · doi:10.1002/cncr.24162 · Cited by 91
“While controversy persists regarding the validity of subtyping melanoma, recent evidence of divergent pathways of melanomagenesis according to anatomic location, sun exposure, nevus count, age of onset, and various mutations (eg, B-RAF, c-Kit) suggest that distinct phenotypic and genotypic patterns of melanoma exist.(…”
BackgroundTargeting drivers of melanoma with synthetic small molecules and phytochemicals
Strickland, L. R., Pal, H. C., Elmets, C. A., & Afaq, F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.016 · Cited by 93
Clonal Architectures and Driver Mutations in Metastatic Melanomas
Ding, L., Kim, M., Kanchi, K., Dees, N. D., Lu, C., Griffith, M., Fenstermacher, D., Sung, H., Miller, C. A., Goetz, B. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111153 · Cited by 91
Spitz Nevus, Spitz Tumor, and Spitzoid Melanoma
Ferrara, G., Gianotti, R., Cavicchini, S., Salviato, T., Zalaudek, I., & Argenziano, G. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.06.012 · Cited by 91
Cancer treatment according to BRCA1 and BRCA2 mutations
Maxwell, K. N., & Domchek, S. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.123 · Cited by 93
Greshock, J. D., Nathanson, K. L., Martin, A., Zhang, L., Coukos, G., Weber, B. L., & Zaks, T. Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3674 · Cited by 94
NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
Tschandl, P., Berghoff, A. S., Preusser, M., Burgstaller-Muehlbacher, S., Pehamberger, H., Okamoto, I., & Kittler, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069639 · Cited by 91
Mucosal malignant melanoma – a clinical, oncological, pathological and genetic survey
Mikkelsen, L. H., Larsen, A., von Buchwald, C., Drzewiecki, K. T., Prause, J. U., & Heegaard, S. (2016) · Apmis · doi:10.1111/apm.12529 · Cited by 92
miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy
Bhattacharya, A., Schmitz, U., Raatz, Y., Schönherr, M., Kottek, T., Schauer, M., Franz, S., Saalbach, A., Anderegg, U., Wolkenhauer, O., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3070 · Cited by 90
Margolin, K. A., Moon, J., Flaherty, L. E., Lao, C. D., Akerley, W., Othus, M. K. D., Sosman, J. A., Kirkwood, J. M., & Sondak, V. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2488 · Cited by 89
Finger, P. T., & Pavlick, A. C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0555-7 · Cited by 89
Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
Luke, J. J., & Hodi, F. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2197 · Cited by 90
BRAF,NRASandHRASmutations in spitzoid tumours and their possible pathogenetic significance
Forno, P. D., Pringle, J. H., Fletcher, A. A., Bamford, M. W., Su, L. D., Potter, L., & Saldanha, G. S. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09181.x · Cited by 89
Historical, Clinical, and Dermoscopic Characteristics of Thin Nodular Melanoma
Kalkhoran, S. M., Milne, O., Zalaudek, I., Puig, S., Malvehy, J., Kelly, J. W., & Marghoob, A. A. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.369 · Cited by 89
An Update on Tumors of the Anal Canal
Shia, J. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0668-rar.1 · Cited by 89
Merkel, E. A., & Gerami, P. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.147 · Cited by 89
Schoenewolf, N. L., Büll, C., Belloni, B., Holzmann, D., Tonolla, S., Lang, R., Mihic‐Probst, D., Andres, C., & Dummer, R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.049 · Cited by 88
Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma
Bonazzi, V., Irwin, D. L., & Hayward, N. K. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20615 · Cited by 88
Climent, J., Dimitrow, P., Fridlyand, J., Palacios, J., Siebert, R., Albertson, D. G., Gray, J. W., Pinkel, D., Lluch, A. M., & Martinez-Climent, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3307 · Cited by 88
Self-citationMelanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma
DeWane, M. E., Kelsey, A., Oliviero, M., Rabinovitz, H. S., & Grant-Kels, J. M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.03.066 · Cited by 88
North, J. P., Garrido, M. C., Kolaitis, N. A., LeBoit, P. E., McCalmont, T. H., & Bastian, B. C. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000189 · Cited by 87
Self-citationTumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
Horn, S., Leonardelli, S., Sucker, A., Schadendorf, D., Griewank, K., & Paschen, A. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx271 · Cited by 87
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Yan, N., Guo, S., Zhang, H., Zhang, Z., Shen, S., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863043 · Cited by 87
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas
Leitão, M. M., Cheng, X., Hamilton, A. L., Siddiqui, N. A., Jurgenliemk-Schulz, I. M., Mahner, S., Åvall-Lundqvist, E. H., Kim, K., & Freyer, G. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000198 · Cited by 87
Kelleher, F. C., & McArthur, G. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824ba4df · Cited by 89
Divergent cancer pathways for early‐onset and late‐onset cutaneous malignant melanoma
Anderson, W. F., Pfeiffer, R. M., Tucker, M. A., & Rosenberg, P. S. (2009) · Cancer · doi:10.1002/cncr.24481 · Cited by 78
Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
Johnson, D. B., Smalley, K. S. M., & Sosman, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3270 · Cited by 87
van de Nes, J. A. P., Gessi, M., Sucker, A., Möller, I., Stiller, M., Horn, S., Scholz, S. L., Pischler, C., Stadtler, N., Schilling, B., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2052-2 · Cited by 87
Practical application of new technologies for melanoma diagnosis
March, J., Hand, M., & Grossman, D. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1138 · Cited by 87
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Zhou, Y., Shen, J. K., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.004 · Cited by 87
Using gold nanoparticles in diagnosis and treatment of melanoma cancer
Bagheri, S., Yasemi, M., Qamsari, E. S., Rashidiani, J., Abkar, M., Hassani, M., Mirhosseini, S. A., & Kooshki, H. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1430585 · Cited by 87
Nevus density and melanoma risk in women: A pooled analysis to test the divergent pathway hypothesis
Olsen, C. M., Zens, M. S., Stukel, T. A., Sacerdote, C., Chang, Y., Armstrong, B. K., Bataille, V. A., Berwick, M., Elwood, M., Holly, E. A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24011 · Cited by 87
The genetics of melanoma: recent advances
Hill, V. K., Gartner, J. J., Samuels, Y., & Goldstein, A. M. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153429 · Cited by 86
Gonzalez-Cao, M., Mayo-de-las-Casas, C., Molina-Vila, M. A., De Mattos-Arruda, L., Muñoz-Couselo, E., Manzano, J. L., Cortes, J., Berros, J. P., Drozdowskyj, A., Sanmamed, M., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000187 · Cited by 79
Zipser, M. C., Eichhoff, O. M., Widmer, D. S., Schlegel, N. C., Schoenewolf, N. L., Stuart, D., Liu, W., Gardner, H., Smith, P. D., Nuciforo, P., et al. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00823.x · Cited by 75
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells
Loria, R., Bon, G., Perotti, V., Gallo, E., Bersani, I., Baldassari, P., Porru, M., Leonetti, C., Carlo, S. E. D., Visca, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2995 · Cited by 86
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma
Martín‐Algarra, S., Espinosa, E., Rubió‐Casadevall, J., López, J. J. L., Manzano, J. L., Alonso-Carrión, L., Plazaola, A., Tanovíc, A., & Paz-Ares, L. G. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.005 · Cited by 86
Liu, S., Wang, H., Currie, B. M., Molinolo, A. A., Leung, H. J., Moayeri, M., Basile, J. R., Alfano, R. W., Gutkind, J. S., Frankel, A. E., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707419200 · Cited by 86
Identification of recurrent mutational events in anorectal melanoma
Yang, H. M., Hsiao, S. J., Schaeffer, D. F., Lai, C. K., Remotti, H. E., Horst, D. A., MANSUKHANI, M. M., & Horst, B. A. J. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.179 · Cited by 86
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
Mignard, C., Deschamps-Huvier, A., Gillibert, A., Modeste, A.-B. D., Dutriaux, C., Khammari, A., Avril, M., Kramkimel, N., Mortier, L., Marcant, P., et al. (2018) · Journal of Oncology · doi:10.1155/2018/1908065 · Cited by 86
Shields, J. M., Thomas, N. E., Cregger, M., Berger, A. J., Leslie, M., Torrice, C., Hao, H., Penland, S., Arbiser, J., Scott, G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3311 · Cited by 81
Multiplex Mutation Screening by Mass Spectrometry
Beadling, C., Heinrich, M. C., Warrick, A., Forbes, E. M., Nelson, D., Justusson, E., Levine, J., Neff, T. L., Patterson, J., Presnell, A., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.04.003 · Cited by 85
Brouwer, N. J., Verdijk, R. M., Heegaard, S., Marinkovic, M., Esmaeli, B., & Jager, M. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100971 · Cited by 85
Unraveling the Wide Spectrum of Melanoma Biomarkers
Revythis, A., Shah, S., Kutka, M., Moschetta, M., Öztürk, M. A., Pappas‐Gogos, G., Ioannidou, E., Sheriff, M., Rassy, E., & Boussios, S. (2021) · Diagnostics · doi:10.3390/diagnostics11081341 · Cited by 85
A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity
Conde‐Perez, A., Gros, G., Longvert, C., Pedersen, M., Petit, V., Aktary, Z., Virós, A., Gesbert, F., Delmas, V., Rambow, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms9093 · Cited by 85
Self-citationGenetic alterations in melanocytic tumors
Takata, M., & Saida, T. (2006) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2006.05.002 · Cited by 85
Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin
Jaimes, N., Marghoob, A. A., Rabinovitz, H. S., Braun, R. P., Cameron, A., Rosendahl, C. O., Canning, G., & Keir, J. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1117 · Cited by 85
Akslen, L. A., Puntervoll, H. E., Bachmann, I. M., Straume, O., Vuhahula, E. A. M., Kumar, R., & Molven, A. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e3282f32517 · Cited by 86
Young, K., Minchom, A. R., & Larkin, J. (2012) · Future Oncology · doi:10.2217/fon.12.43 · Cited by 91
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 87
The miRNAs Role in Melanoma and in Its Resistance to Therapy
Varrone, F., & Caputo, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030878 · Cited by 85
Huang, B., Han, W., Sheng, Z.-F., & Shen, G. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01271-2 · Cited by 84
Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies
Scatena, C., Murtas, D., & Tomei, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635488 · Cited by 86
A melanocyte–melanoma precursor niche in sweat glands of volar skin
Okamoto, N., Aoto, T., Uhara, H., Yamazaki, S., Akutsu, H., Umezawa, A., Nakauchi, H., Miyachi, Y., Saida, T., & Nishimura, E. K. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12297 · Cited by 73
Ambiguous Melanocytic Tumors With Loss of 3p21
Yeh, I., Mully, T. W., Wiesner, T., Vemula, S. S., Mirza, S. A., Sparatta, A. J., McCalmont, T. H., Bastian, B. C., & LeBoit, P. E. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000209 · Cited by 84
Self-citationA Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Kashani–Sabet, M., Venna, S. S., Nosrati, M., Rangel, J., Sucker, A., Egberts, F., Baehner, F. L., Simko, J. P., Leong, S. P. L., Haqq, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1777 · Cited by 84
Pedersen, M., Küsters‐Vandevelde, H. V. N., Virós, A., Groenen, P. J. T. A., Sánchez‐Laorden, B. L., Gilhuis, J. H., Grunsven, I. A. V. E.-V., Renier, W. O., Schieving, J., Niculescu‐Duvaz, I., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0464 · Cited by 85
B-Raf Inhibition in the Clinic: Present and Future
Fiskus, W. C., & Mitsiades, N. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-030732 · Cited by 85
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival
Roh, M. R., Gupta, S., Park, K.-H., Chung, K. Y., Lauss, M., Flaherty, K. T., Jonsson, G. G., Rha, S. Y., & Tsao, H. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.01.024 · Cited by 88
Clinical Pharmacokinetics of Vemurafenib
Zhang, W., Heinzmann, D., & Grippo, J. F. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0523-7 · Cited by 86
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Kim, H. J., & Kim, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052984 · Cited by 84
Wang, L., Rao, M., Fang, Y., Hameed, M., Viale, A. J., BUSAM, K. J., & Jhanwar, S. C. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.04.001 · Cited by 83
Self-citationDetection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients
Daniotti, M., Vallacchi, V., Rivoltini, L., Patuzzo, R., Santinami, M., Arienti, F., Cutolo, G., Pierotti, M. A., Parmiani, G., & Rodolfo, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22598 · Cited by 76
Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?
van den Bosch, T., Kılıç, E., Paridaens, D. A., & de Klein, A. (2010) · Dermatology Research and Practice · doi:10.1155/2010/360136 · Cited by 83
Molecular Pathology of Skin Neoplasms of the Head and Neck
Kraft, S., & Granter, S. R. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0157-ra · Cited by 83
Is superficial spreading melanoma still the most common form of malignant melanoma?
Forman, S. B., Ferringer, T., Peckham, S. J., Dalton, S. R., Sasaki, G. T., Libow, L. F., & Elston, D. M. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.10.650 · Cited by 83
Curiel‐Lewandrowski, C. N., Nijsten, T. E. C., Gomez, M. L., Hollestein, L. M., Atkins, M. B., & Stern, R. S. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.58 · Cited by 82
Copy Number Gains in 11q13 and 8q34 Are Highly Linked to Prognosis in Cutaneous Malignant Melanoma
Gerami, P., Jewell, S. S., Pouryazdanparast, P., Wayne, J. D., Haghighat, Z., BUSAM, K. J., RADEMAKER, A. W., & Morrison, L. E. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.01.011 · Cited by 82
Self-citationDistinct melanoma types based on reflectance confocal microscopy
Pellacani, G., Pace, B. D., Reggiani, C., Cesinaro, A. M., Argenziano, G., Zalaudek, I., Soyer, H. P., & Longo, C. (2014) · Experimental Dermatology · doi:10.1111/exd.12417 · Cited by 82
Treatment of cutaneous melanoma: current approaches and future prospects
DAUD, A. I., Algazi, A., & Soon, C. (2010) · Cancer Management and Research · doi:10.2147/cmar.s6073 · Cited by 84
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.